Potential hidden Plasmodium vivax malaria reservoirs from low

parasitemia Duffy-negative Ethiopians: molecular evidence

- 4 Abnet Abebe^{1,2*}, Isabelle Bouyssou^{3,4}, Solenne Mabilotte⁵, Sisay Dugassa¹, Ashenafi Assefa^{2,6},
- 5 Jonathan J. Juliano⁷, Eugenia Lo⁸, Didier Menard^{3,5,9,10}, Lemu Golassa^{1*}

Affiliations

- 9 Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Ethiopia.
- ² Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
- ³ Institut Pasteur, Université Paris Cité, Malaria Genetics and Resistance Unit, INSERM U1201, F-75015
- 12 Paris, France.

1

2

6 7 8

- ⁴ Sorbonne Université, Collège Doctoral ED 515 Complexité du Vivant, F-75015 Paris, France.
- ⁵ Université de Strasbourg, Institute of Parasitology and Tropical Diseases, UR7292 Dynamics of Host-
- Pathogen Interactions, F-67000 Strasbourg, France.
- ⁶ Institute of Infectious Disease and Global Health, University of North Carolina at Chapel Hill, Chapel
- 17 Hill, NC, USA.
- ⁷ Division of Infectious Disease, School of Medicine, University of North Carolina at Chapel Hill, Chapel
- 19 Hill, NC, USA.
- ⁸ Department of Biological Sciences, Bioinformatics Research Center, University of North Carolina at
- 21 Charlotte, USA.
- ⁹ Institut Pasteur, Université Paris Cité, Malaria Parasite Biology and Vaccines Unit, F-75015 Paris,
- France.
- 24 ¹⁰ CHU Strasbourg, Laboratory of Parasitology and Medical Mycology, F-67000 Strasbourg,
- 25 France

26 27

28

*Corresponding authors; E-mail:

- 29 Abnet Abebe: <u>abnetabas@gmail.com</u>
- 30 Phone: +251911701745; P.O. Box 24756; Addis Ababa, Ethiopia
- 31 Lemu Golassa: lgolassa@gmail.com
- 32 Phone: +251911371981

Abstract

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

Background: The interaction between the *Plasmodium vivax* Duffy-binding protein and the corresponding Duffy Antigen Receptor for Chemokines (DARC) is primarily responsible for the invasion of reticulocytes by P. vivax. The Duffy-negative host phenotype, highly prevalent in sub-Saharan Africa, is caused by a single point mutation in the GATA-1 transcription factor binding site of the DARC gene promoter. The aim of this study was to assess the Duffy status of patients with *P. vivax* infection from different study sites in Ethiopia. **Methods:** A cross-sectional study was conducted from February 2021 to September 2022 at five varying eco-epidemiological malaria endemic sites in Ethiopia. Outpatients who were diagnosed with P. vivax infection (pure and mixed P. vivax/P. falciparum) by microscopy were subjected to qPCR genotyping at the DARC promoter. The associations between P. vivax infection, host genotypes and other factors were evaluated. **Result:** In total, 361 patients with *P. vivax* infection were included in the study. Patients with pure P. vivax infections accounted for 89.8% (324/361), while the remaining 10.2% (37/361) had mixed P. vivax/P. falciparum infections. About 95.6% (345/361) of the participants were Duffypositives (21.2% homozygous and 78.8%, heterozygous) and 4.4% (16/361) were Duffynegatives. The mean asexual parasite density in homozygous and heterozygous Duffy-positives was 12,165 p/ μ l (IQR25-75: 1,640-24,234 p/ μ l) and11,655 p/ μ l (IQR25-75: 1,676-14,065 p/ μ l), respectively, significantly higher than that in Duffy-negatives (1,227p/µl; IQR25-75: 539- $1,732p/\mu l$). **Conclusion:** This study confirms that Duffy-negativity does not provide complete protection against P. vivax infection. The development of P. vivax-specific elimination strategies, including alternative antimalarial vaccines should be facilitated by a better understanding of the

epidemiological landscape of vivax malaria in Africa. More importantly, low parasitemia associated with P. vivax infections in Duffy-negative patients may represent hidden reservoirs of transmission in Ethiopia. **Key Words**: *Plasmodium vivax*, Duffy, heterozygous, homozygous, malaria, Ethiopia **Author Summary** Plasmodium vivax generally receives less attention than P. falciparum and was neglected in sub-Saharan Africa. However, the characteristics of *P. vivax* infection in Duffy-negative individuals, and the distribution of Duffy blood group in different eco-epidemiological zones and ethnic groups of Ethiopia are not well documented. Here, we determined the Duffy genotypes of P. vivax infected patients across broad regions of Ethiopia. It is clear that Duffy negative individuals in Ethiopia are not fully protected against *P. vivax* infection, and that these infections in Duffy negatives are often associated with low parasitemia. Our findings lend support to the notion that *P. vivax* may have developed a Duffy-independent erythrocyte invasion pathway and/or evolution in host immune responses.

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

Introduction In 2021, there were an estimated 247 million cases and 619,000 deaths from malaria worldwide. Of these, 2% of the cases were due to *P. vivax*, mainly in the Horn of Africa, South America, India and Asia (1). P. vivax malaria is recognized as a cause of severe morbidity and mortality, with a significant negative impact on health in endemic countries (2–4). The unique biological features of P. vivax, such as hypnozoite formation and early gametocytogenesis, pose a challenge to global malaria elimination efforts (5). The P. vivax invasion pathway into reticulocytes was previously thought to be primarily dependent on the interaction between the Duffy binding protein (PvDBP) and its cognate receptor, the Duffy Antigen Receptor for Chemokines (DARC) (6–8). Polymorphisms in the promoter of the DARC gene alter the expression of the Duffy antigen protein and determine an individual's Duffy blood group (9). A point mutation in the GATA-1 transcription factor binding site of the promoter of the gene at position-67 encodes the change of a T nucleotide to a C nucleotide and underlies the Duffy-negative (erythrocyte silent) phenotype (10–12). Individuals with this mutation do not express the Duffy antigen on the surface of their erythrocytes (13). Duffy-negative phenotype in the population occurs at low frequency in Caucasians ($\sim 3.5\%$) (14), and has a prevalence of almost 100% in West Africa, > 80% in African Americans (15), 20-36% in East Africa and 84% in southern Africa (16). In Ethiopia, a study reported 94/416 (~23%) of the febrile patients from the six health centres/hospitals were Duffy-negatives, though only two of them were confirmed with P. vivax (17). The scientific paradigm that P. vivax exclusively invades Duffy-positive reticulocytes through

the interactions of PvDBP and DARC was established, and it was assumed that vivax malaria was

rarely transmitted or even absent in regions where Duffy-negativity predominates, such as sub-

Saharan Africa (18,19). However, recent studies have shown that P. vivax can infect Duffynegative reticulocytes (20), and is no longer a barrier to such infections (21). In East Africa, the prevalence of P. vivax in Duffy-negative populations ranges from 3% (22) to \sim 12% in Ethiopia(16) and 3%(16) to \sim 18% in Sudan (9). Although several studies have demonstrated the presence of P. vivax infection in Duffy-negative individuals, the distribution of these infections in different eco-epidemiological zones and ethnic groups are not well documented, especially in Ethiopia. This study compares the prevalence of Duffy blood group genotypes of P. vivax infected patients among different eco-epidemiological zones of Ethiopia.

Materials and Methods

Study design, period and areas

A health-facility based cross-sectional study was conducted from February 2021 to September 2022. Based on the annual parasite index (API), malaria risk stratification in Ethiopia is divided into five classes: i) malaria free, ii) very low, iii) low, iv) moderate and v) high malaria risk. The study sites were selected from different malaria risk stratification areas. The sites include: Arbaminch, Dubti, Gambella, Metehara, and Shewarobit (*Figure 1*). Arbaminch hospital is located in the Southern Nation and Nationalities People Regional State in the southern part of the country (altitude 1200 m; Lat, Long: 6.02043, 37.56788); Dubti hospital is located in the Afar Regional State in the northern-east part of the country (altitude 379 m; Lat, Long: 11.72654, 41.09440); Gambella hospital is located in Gambella Regional State in the western part of the country (altitude 447 m; Lat, Long: 8.24810, 34.59071); Metehara hospital is located in Oromia Regional State in the eastern part of the country (altitude 959 m, Lat, Long: 8.89932, 39.91726);

and Shewarobit hospital is located in Amhara Regional State in the northern part of the country (altitude 1268 m; Lat, Long: 10.01734, 39.91253).




Figure 1. A map of the study sites with malaria risk stratification background, Ethiopia.

Sample collection

Blood samples diagnosed positive for *P. vivax* (pure or mixed *P. vivax/P. falciparum*) by qPCR from patients seen at health facilities were included to determine their Duffy status. The sample size was calculated based on the proportion of Duffy-negative (20%) cases previously reported in Ethiopia (23).

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

Malaria diagnosis by Rapid Diagnostic Tests (RDT) and microscopy Finger prick blood samples were collected from self-reported febrile patients seeking malaria diagnosis at a participating health centre. The malaria laboratory diagnosis was carried out for each suspected malaria patient using RDT and microscopy. SD BIOLINE Malaria Ag Pf/Pv (05FK80) RDT was used for the detection of HRP-II (Histidine-rich protein II) specific for P. falciparum and Plasmodium lactate dehydrogenase (pLDH) specific for P. vivax. Five microliters (5µl) of sample were obtained for the test and the result was interpreted after 15 minutes (up to 30 minutes) according to the manufacturer's guidelines. Thick and thin blood films (stained with 10% Giemsa staining solution - pH 7.2 - for 10 minutes) were prepared from finger-prick blood samples. Parasite densities were determined on thick films by expert malaria microscopists for both sexual and asexual stages of the parasites, considering a minimum of 200 WBCs, the reported number of parasites per microliter of blood, assuming a total white blood cell count of 8000/µL. P. vivax sexual stages/gametocytes quantification was performed on the blood film with P. vivax (pure) and a mixed species (P. vivax/P. falciparum). Parasitemia was then classified as low (<1000 parasites per microliter of blood), intermediate (1000-4999 parasites per microliter of blood) and high (≥5000 parasites per microliter of blood) (24). Slides were declared negative after examination of at least 100 highpower microscope fields (25). Blood film slides were re-examined and quantified by WHO certified malaria microscopists. Patients who were positive for P. vivax (pure) and mixed P. vivax/P. falciparum infection by both RDT and microscopy were included in the study. Venous blood samples were collected and spotted onto WhatmanTM 903 Protein Saver Card, US (Dried Blood Spot, DBS), for molecular analysis of the Duffy genotypes.

DNA extraction and molecular diagnosis of *Plasmodium* species

Genomic DNA (human and parasite) was extracted from a 6 mm diameter spot of a DBS sample and eluted in 100µl of TE Buffer (Tris-EDTA) using the QIAamp DNA Extraction Kit (Cat.No: 79216, Lot: 172018338, Germany) according to the manufacturer's instructions for the molecular identification of malaria parasites and Duffy genotypes. The extracted DNA was stored at -20°C for further use.

Primers previously designed to target the mitochondrial species-specific *cytochrome b (cytb)* gene were used for the detection and identification of *P. vivax* and *P. falciparum* (*Table 1*). Given the multiple copies of the mitochondria, this assay allows the detection of low density *Plasmodium* infections in malaria pre-elimination settings (26).

Table 1. Species-specific primers used for the detection and the species identification of P. vivax and P. falciparum.

Species	Forward or Reverse	Primer
P. vivax	Forward	5`- TGCTACAGGTGCATCTCTTGTATTC -3'
	Reverse	5`- ATTTGTCCCCAAGGTAAAACG -3'
P. falciparum	Forward	5`- ATGGATATCTGGATTGATTTATTTATGA -3'
V I	Reverse	5`- TCCTCCACATATCCAAATTACTGC -3'

The PCR amplifications were carried out using 10 μ L of Advanced Mix Sybgreen (2x) (Catalog # 1725271, Bio-Rad laboratories Inc. United State), 4 μ L of water, 0.5 μ L of each primer, and 5 μ L of DNA template with the final volume of 20 μ L in a Bio-Rad CFX96TM Real-Time PCR detection system.

Molecular Identification of the Duffy genotypes

Molecular identification of the Duffy genotype was based on a novel sequence-specific PCR primers (Amplification Refractory Mutation System, ARMS) that allows amplifications of the GATA-1 transcription factor-binding site of the *DARC* gene promoter only when the target allele (TCT for Duffy-positive and CCT for Duffy-negative genotypes) is detected in the sample. Different sets of primers were designed and tested using Duffy-positive and Duffy-negative DNA controls which were validated by PCR and Sanger sequencing (see **S1** *Appendix A*) (27) to detect the Duffy genotype by qPCR. The forward primers contain a nucleotide mismatch at the 3' end (T for Duffy-positive and C for Duffy-negative genotypes) in addition to a mismatch base near to the SNP at the 3' end (C for Duffy-positive and A for Duffy-negative genotypes), to avoid false-amplification and prevent binding to non-complementary sequence and terminate amplification. The reverse primer are the same (*Table 2*). All Duffy negative samples found by PCR ARMS have been confirmed by Sanger sequencing.

Table 2: AMRS PCR primers used for the detection of Duffy-positive and -negative genotypes.

Duffy	Forward or				
genotype	Reverse	Primer			
positive	Forward	5`- CCCTCATTAGTCCTTGGCTCTCAT -3'			
positive	Reverse	5`- CACCCTGTGCAGACAGTTCC -3'			
negative	Forward	5`- CCCTCATTAGTCCTTGGCTCTAAC -3'			
	Reverse	5`- CACCCTGTGCAGACAGTTCC -3'			

Briefly, polymorphisms in the GATA-1 were detected in two separate real-time PCR reactions. Real-time PCR reactions were performed with 10 μL of ssAdvanced mix sybgreen 2x, 10μM of primers and 5 μL of DNA extract, and amplified on the CFX96 PCR instrument (Bio-Rad, Marnes-la-Coquette, France). PCR amplification was carried out under the following conditions: heating at 98 °C for 3 min, followed by 35 cycles of heating at 95 °C for 20 s, and of annealing/extension at 62 °C for 30 s and a final extension step at 72°C for 10 min. After completion of the amplification reaction, a melting curve (65-90°C) was generated to detect non-specific PCR amplification. For each run, homozygous (TCT/TCT), heterozygous (TCT/CCT) Duffy-positive, and homozygous Duffy-negative (CCT/CCT) samples were included as positive controls and a no template (water) as negative control (see **S1** *Appendix B*).

Statistical analyses

207

208

209

210

211

212

213

214

215

216

217

218

219

223

224

225

- Data were analysed using Statistical Package for Social Sciences (SPSS, version 25). Chi-
- squared, or Fisher's exact tests were used for frequency data (expressed as percentages).
- Associations between Duffy genotypes and different variables were assessed using Fisher's exact
- test. Two-sided p-values less than 0.05 were considered as statistically significant.

Ethical statement

- Ethical approval was obtained from Aklilu Lema Institute of Pathobiology Institutional Review
- Board (IRB) (Ref No: ALIPB IRB/34/2013/20), Addis Ababa University, Addis Ababa,
- 227 Ethiopia. An official letter was sent to the study sites and the study was initiated after obtaining
- 228 permission from the respective health facilities. Written informed consent and/or assent was
- obtained from all study participants, using the local language where appropriate.

Results

Characteristics of study participants. A total of 361 PCR-confirmed *P. vivax* (mono or mixed) infected samples were included for the molecular analysis of Duffy status. Among them, 126 (34.9%) were female, the mean age was 25 years old (ranging from 1-80 years old), 108 (29.9%) had no occupation, and 152 (42.1%) participants live in rural areas (*Table 3*).

Table 3. Sociodemographic characteristics of study participants in Ethiopia (n=361)

Variables	Category	Number	Percent (%)
Candan	Female	126	34.9
Gender	Male	235	65.1
	≤14	40	11.1
Age stratification	15-24	135	37.4
in years	25-34	122	33.8
	≥35	64	17.7
	Amhara	106	29.4
	Anuak	13	3.6
	Somale	6	1.7
Ethnic	Oromo	76	21.1
Eunic	Afar	52	14.4
	Tigre	11	3.0
	Welayita	30	8.3
	Gamo	37	10.2

	Sidama	11	3.0
	Hadiya	3	0.8
	Nuer	16	4.4
	Arbaminch	74	20.5
	Dubti	68	18.8
Study Sites	Gambella	74	20.5
	Metehara	75	20.8
	Shewarobit	70	19.4

Based on Duffy genotyping, 345 (95.6%) of the *P. vivax* patients were Duffy-positives (272 (78.8%) were heterozygous and 73 (21.2%) were homozygous) and 16 (4.4%) were Duffynegatives.




Figure 2. Pie chart of Duffy status of study participants, Ethiopia (n=361)

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

Distribution of the Duffy genotypes by study sites, study participants, ethnicity, gender, and age. Amongst the 361 samples tested, 73 (20.2%) were TCT/TCT, 272 (75.4%) were TCT/CCT and 16 (4.4%) were CCT/CCT. The Duffy-negative patients (CCT/CCT genotype) from Arbaminch, Gambella, Metehara and Shewa robit was 2.7%, 8.1%, 4.0%, and 7.1%, respectively (*Figure 3*). No Duffy-negatives were detected from Dubti. The highest proportion of Duffy-negatives was in Gambella (8.1%, 6/74) and the lowest in Arbaminch (2.7%, 2/74). There was no significant association between Duffy genotype and study site (p=0.12). The highest proportion of Duffynegatives was observed in the Nuer ethnic group (12.5%, 2/16) followed by the Agnuwak group (7.7%, 1/13). No Duffy-negatives was identified among the Somale, Afar, Tigre, Welayita and Hadiya ethnic groups. No significant association was found between Duffy genotype and ethnic group (p=0.50). About 5.5% (13/235) male and 2.4% (3/126) female participants were Duffynegatives, with no significant association between Duffy genotype and gender (p=0.16). From different age stratification(22), the lowest proportion of Duffy-negatives was identified from the age groups ≤ 14 (2.5%, 1/40) and 25-34 (2.5%, 3/122), while the highest proportion was identified from the age group ≥ 35 (7.8%, 5/64), no significant association between Duffy genotype and age groups (p=0.337). (**Table 4**). Similarly, among the Duffy-positive participants, the relative proportions of heterozygous and homozygous were not associated with either study site (p=0.47), ethnic group (p=0.47) or gender (p=0.17) (**Table 5**).




Figure 3. Map showing the distribution of the Duffy genotypes at five different malaria endemic sites in Ethiopia.

Table 4. Analysis of Duffy status by study sites (altitude), study participants ethnicity and gender (n=361)

		Duffy Status			Chi-	
	Variables	Positive	Negative	Total	Square	p-value
		n (%)	n (%)	Total	Square	
Study	Arbaminch(1200 m)	72 (97.3)	2 (2.7)	74	7.284	0.12

sites	Dubti (379 m)	68 (100)	0	68		
(altitude)	Gambella (447 m)	68 (91.9)	6 (8.1)	74		
	Metehara (959 m)	72 (96.0)	3 (4.0)	75	-	
	Shewarobit(1268 m)	65 (92.9)	5 (7.1)	70	-	
	Amhara	100 (94.3)	6 (5.7)	106		
	Agnuwak	12 (92.3)	1 (7.7)	13		
	Somale	6 (100	0	6		
Ethnic of	Oromo	71 (93.4)	5 (6.6)	76	-	
Study	Afar	52 (100)	0	52	-	
participa	Tigre	11 (100)	0	11	9.313	0.50
nts	welayita	30 (100)	0	30	-	
	Gamo	35 (94.6)	2 (5.4	37		
	Sidama	11 (100)	0 (0)	11		
	Hadiya	3 (100%	0	3		
	Nuer	14 (87.5)	2 (12.5)	16		
Gender	Female	123 (97.6)	3(2.4)	126	1.923	0.16
Genuel	Male	222 (94.5)	13(5.5)	235	. 1.923	0.10
	≤14	39(97.5%)	1 (2.5%)	40		
Age in	15-24	128(94.8%)	7 (5.2%)	135	3.381	0.337
years	25-34	119(97.5%)	3 (2.5%)	122	J.J01	0.331
	≥35	59 (92.2%)	5 (7.8%)	64		

Table 5. Analysis of heterozygous and homozygous Duffy positive patients with study site (altitude), ethnicity, and gender (n = 312)

275

		Du	Chi-			
Vari	ables	Homozygous	Heterozygous	Total	Square	p-value
		n (%)	n (%)			
	Arbaminch	20 (27.8)	52 (72.2)	72		
Study Sites	Dubti	12 (17.6)	56 (82.4)	68		
(altitude)	Gambella	16 (23.5)	52 (76.5)	68	3.546	0.47
(4222440)	Metehara	12 (16.7)	60 (83.3)	72		
	Shewarobit	13 (20.0)	52 (80.0)	65	-	
	Amhara	20 (20.0)	80 (80.0)	100		
	Agnuwak	4 (33.3)	8 (66.7)	12		
	Somale	0 (0.0)	6 (100)	6		
	Oromo	13 (18.3)	58 (81.7)	71		
Ethnicity of	Afar	10 (19.2)	42 (80.8)	52		
study	Tigre	2 (18.2)	9 (81.8)	11	9.608	0.47
participants	welayita	7 (23.3)	23 (76.7)	30		
	Gamo	10 (28.6)	25 (71.4)	35		
	Sidama	5 (45.5)	6 (54.5)	11		
	Hadiya	0 (0)	3 (100)	3		
	Nuer	2 (14.3)	12 (85.7)	14		
Gender	Female	31 (25.2)	92 (74.8)	123	1.874	0.17

	Male	42 (18.9)	180 (81.1)	222		
	≤14	4 (10.3%)	35 (89.7%)	39		
Age in	15-24	31 (24.2%)	97 (75.8%)	128	2 901	0.294
years	25-34	24 (20.2%)	95 (79.8%)	119	3.801	0.284
	≥35	14 (23.7%)	45 (76.3%)	59	-	

Distribution of the Duffy genotype by P. vivax infections.

For the 16 *P. vivax* infections in Duffy negatives, 12 (75%) were mono-infection and four (25%) were mixed *P. vivax/P. falciparum* infections. For the 345 *P. vivax* infections in Duffy positives, 312 (90%) were mono-infections and 33 (\sim 10%) were mixed *P. vivax/P. falciparum* infections. The proportion of mixed *P. vivax/P. falciparum* infections was two-fold higher in Duffy-negative than in Duffy positive individuals (p=0.047), despite small samples for the Duffy negatives ($Table\ 6$). Of the 73 homozygous Duffy-positives, 68 (93.2%) were pure P. vivax infections and 5 (6.8%) were mixed P. vivax/P. falciparum infections, slightly lower than that observed in heterozygous Duffy-positives of which 244 (78.2%) were pure P. vivax infections and 28 (10.3%) were mixed P. vivax/P. falciparum infections (p=0.37) ($Table\ 6$).

Table 6. Analysis of P. vivax pure and mixed P. vivax/P. falciparum infections with Duffy genotype (n=361).

Variables		P. vivax infections			Chi-	P-
		Pure n (%)	Mixed n (%)	Total	Square	value
Duffy	positive	312 (90.4)	33 (9.6)	345	3.96	0.047

genotype	negative	12 (75)	4 (25)	16		
	Total	324 (89.8)	37 (10.2)	361		
Duffy	homozygous	68 (93.2)	5 (6.8)	73	0.79	0.37
Positive	heterozygous	244 (89.7)	28 (10.3)	272		
	Total	312 (90.4)	33 (9.6)	345		


Asexual and sexual parasitemia comparison by Duffy groups

Of the samples with an asexual stage density of <1,000 p/ μ L and ranging from 1,000 to 4,999 p/ μ L, 9/60 (15.0%) and 7/131 (5.3%) were obtained from Duffy-negative individuals, respectively. Interestingly, no Duffy-negatives were detected with asexual parasite density \geq 5000 p/ μ L but only Duffy positive patients (n=170; *Table 7*). The mean asexual parasite density in homozygous and heterozygous Duffy-positives was 12,165 p/ μ l (IQR25-75: 1,640-24,234 p/ μ l) and11,655 p/ μ l (IQR25-75: 1,676-14,065 p/ μ l), respectively, significantly higher than that in Duffy-negatives (1,227p/ μ l; IQR25-75: 539-1,732p/ μ l) (p<0.001; *Figure 4*). Of the samples with a sexual gametocytemia of <1,000 p/ μ L, 8/180 (4.4%) were detected in Duffy-negative individuals (*Table 7*). The other eight *P. vivax* infections in Duffy negatives were detected with no gametocytes. By contrast, 172/180 (95.6%) of the Duffy-positives were detected with sexual gametocytemia of <1,000 p/ μ L, 31 were detected with gametocytemia of 1,000-4999 p/ μ L, and 4 with gametocytemia of \geq 5,000 p/ μ L.

Table 7. Association of Duffy status with asexual parasite density (n=361)

	Duffy Status			Chi-	
Variables	Positive	Negative	Total	Square	p-value

		n (%)	n (%)			
Asexual	<1000	51 (85.0)	9 (15.0)	60		
stage	1000-4999	124 (94.7)	7 (5.3)	131	23.96	< 0.001
density	≥5000	170 (100)	0 (0)	170		



Key: Fy+/+; homozygous Duffy-positive, Fy+/-; Heterozygous Duffy-positive, Fy-/-; Duffy-negative

Figure 4: Box plot showing the distribution of asexual parasite density among identified Duffy status.

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

Discussion We report here the association between 361 pure P. vivax and mixed P. vivax/P. falciparum infections collected from five eco-epidemiological study sites in Ethiopia and the Duffy genotype of the patients. We assessed malaria infection by qPCR and polymorphisms in the GATA-1 promoter affecting Duffy status by a novel ARMS-PCR approach. Here, we observed that the proportion of Duffy-negative (4.4%) among *P.vivax* infected patients was lower than previous studies conducted in different countries; Madagascar (9.3%)(27), different parts of Ethiopia (10.5–11.9%)(16), and Sudan 17.9% (9), but relatively higher than study reports such as Ethiopia 2.9%(22), south-eastern Iran 1.3%(28), Brazilian Amazon 0.6%(18). Duffy blood groups remain highly polymorphic between different populations (29). Historically, individuals with the Duffy-negative phenotype were thought to be resistant to P. vivax infection (18,19,30– 32), but recent reports have shown P. vivax infection in Duffy-negative individuals (20,33–37) in many parts of Africa. This study identified 4.4% (16/361) P. vivax infections in Duffy-negative patients. This is different from Central or West Africa, where the Duffy-negative genotype is much more common and almost all P. vivax infections occur among Duffy-negative individuals (36,38,39), despite relatively low number of P. vivax cases compared to East Africa. Several hypotheses have been put forward to explain the change in the pattern of infection in Duffy-negative individuals. One is a change in the host susceptibility, which in turn may drastically affect the distribution of P. vivax (9) and another is that P. vivax may have evolved to adapt to a wider range of hosts, environments, and highly competent transmission vectors in Africa (33). Alternatively, P. vivax parasites may have developed alternative mechanisms to bind and invade

reticulocytes as other host cell receptors have been shown to be involved in erythrocyte invasion (40).

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

Polymorphisms in Duffy blood group among different ethnic groups may contribute to the changing epidemiology of vivax malaria in Africa (41). The Ethiopian population has a very heterogeneous ethnic composition. Eleven different ethnic groups were included in this study and the proportion of Duffy-negative and Duffy-positive varied between ethnic groups and study sites. A high proportion of Duffy-negative samples were observed among the Nuer followed by the Agnuwak ethnic groups, but no Duffy-negative was identified among the Somale, Afar, Tigre, Welayita and Hadiya ethnic groups. Other studies have also showed variation of Duffy genotype between ethnic groups. For example, in Sudan the Duffy-negative phenotype was identified in 83% of Shagia and 77% of Manasir tribes (42); in Mauritania 54% of Moors were Duffy-positives while only 2% of black ethnic groups were Duffy-positives (41); in Colombia Duffy genotypes were significantly associated with ethnicity (43). These findings suggest that ethnic groups may be genetically distinct, resulting in different levels of susceptibility to P. vivax infection, in addition to different hypothesis such as P. vivax trains with a new capacity for erythrocyte invasion(27), or use several receptor-ligand interactions to tightly bind erythrocytes in the absence of a Duffy receptor(21). Duffy-negatives with pure P. vivax and mixed P. vivax/P. falciparum infections was identified in the current study. The proportion of mixed P. vivax/P. falciparum infections in Duffy-negative was 25% in the present study, which was similar with the findings from Nigeria (25%)(45), and Cameroon (25%)(44), while it was lower than the study conducted in

Madagascar (26.7%)(46), and Democratic Republic of the Congo (64%)(38). The results provide

evidence that Duffy-negative individuals can be infected by pure *P. vivax* alone or together with *P. falciparum*.

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

The mean asexual parasite density among Duffy-negatives (CCT/CCT) was 1,227 p/ul, around tenfold lower compared to homozygous Duffy-positives (TCT/TCT; 12,165 p/µl) and heterozygous Duffy-positive (TCT/CCT; 11,655 p/ μ l). Several prior studies have shown that P. vivax infections observed in Duffy-negatives have a significantly lower parasitemia than in Duffy-positive infections and are asymptomatic (13)(16). The low parasite densities found in Duffy-negative malaria patients may indicate that *P. vivax* uses an alternative pathway to invade Duffy-negative reticulocytes, which can be much less efficient than the classical pathway involving the interaction between PvDBP and DARC (22). Alternatively, it has been hypothesized that the reticulocytes of Duffy-negative individuals may express the DARC protein in a transient and weak manner, thereby mediating a low invasion capacity (16). Among the 16 Duffy negative samples detected in this study, half were detected with low-level gametocytes. The presence of gametocytes among Duffy negatives may further imply that these infections have the potential contributing to onward transmission. To conclude, this study reports heterogeneous proportions of Duffy-negative individuals among P. vivax malaria patients across Ethiopia, confirms that Duffy-negativity does not provide complete protection against P. vivax infection, and these infections are often associated with low parasitemia, which may represent hidden reservoirs that can contribute to transmission. Therefore, the development of *P. vivax*-specific elimination strategies, including alternative antimalarial vaccines other than a Duffy-binding protein-based vaccine, should be facilitated by a better understanding of the relationship between Duffy-negativity and the invasion mechanisms of P. vivax.

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

Abbreviations ALIPB: Aklilu Lema Institute of Pathobiology; *DARC*: Duffy antigen receptor for chemokines; DBP: Duffy Binding Protein; DBS: Dried Blood Spots; DNA: Deoxyribonucleic Acid; EPHI: Ethiopian Public Health Institute; HRP: Histidine-rich protein; IRB: Institutional Review Board; MoE: Ministry of Education; NSP: National Strategic Plan; pLDH: Plasmodium lactate dehydrogenase; Pv/Pf: Plasmodium vivax and Plasmodium falciparum; RDT: Rapid Diagnostic Tests; RT PCR: Real Time Polymerase Chain Reaction; SNP: Single Nucleotide Polymorphism; SOP: Standard Operating Procedures; SPSS: Statistical Package for Social Sciences; WBC: White Blood Cells; WHO: World Health Organization Acknowledgements This work was supported by i) SIDA project, ii) Human, Heredity and Health in Africa (H3Africa) [H3A-18-002]. H3Africa is managed by the Science for Africa Foundation (SFA Foundation) in partnership with Wellcome, NIH and AfSHG and iii) the Institute Pasteur, Paris, the University of Strasbourg, and the French Government (Agence Nationale de la Recherche; ANR- 18-CE15-0026, ANR-21-CE35-0006 and the Laboratoire d'Excellence 'French Parasitology Alliance for Health Care', ANR-11-15 LABX-0024-PARAFRAP), and iv) EPHI. We would like to thank all the individuals who contributed technically to this study: the laboratory staff at the study sites, the staff at ALIPB (parasitology department), the staff at the Institute of Parasitology and Tropical Diseases, University of Strasbourg (Cécile Doderer-Lang), and the statisticians (Dereje Dilu, Abriham Keraleme and Chalie). We must express our sincere

gratitude to all the regional health offices and the study sites for their cooperation. Last but not least, our sincere thanks go to all the participants who took part in this study. **Authors Contribution** AA: Abnet Abebe, IB: Isabelle Bouyssou, SM: Solenne Mabilotte, SD: Sisay Dugassa, AA2: Ashenafi Assefa, JJ: Jonathan Juliano, DM: Didier Menard, LG: Lemu Golassa Conceptualization and Design: AA, LG Drafting Proposal: AA Revision: AA, LG, DM, SD, AA2, JJ Data Collection: AA, LG, AA2, SD Laboratory analysis: AA, IB, SM, DM, LG Validation: AA, LG, DM, SD, AA2, JJ Writing manuscript – draft: AA Writing manuscript-review & editing: AA, LG, DM, SD, AA2, JJ

References

430

452

431 1. World Health Organization (WHO). World Malaria Report 2022. 432 https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022. 433 434 2. Poespoprodio JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, et al. Vivax malaria: A major cause of morbidity in early infancy. Clinical Infectious Diseases. 435 2009;48(12):1704–12. 436 3. Kevin Baird J. Evidence and implications of mortality associated with acute plasmodium 437 vivax malaria. Clinical Microbiology Reviews. 2013;26(1):36–57. 438 4. Moreira CM, Abo-Shehada M, Price RN, Drakeley CJ. A systematic review of sub-439 microscopic Plasmodium vivax infection. Malaria Journal. 2015;14(1):1–10. 440 Abebe A, Golassa L, Janies DA, Yewhalaw D, Lo E. Gene Polymorphisms Among 5. 441 Plasmodium vivax Geographical Isolates and the Potential as New Biomarkers for 442 Gametocyte Detection. 2022;11(January):1–12. 443 Asok Caudhurit, Julia Polyakovat, Valerea Zbrzenat, Kennett William, Subhash Gulati 6. 444 445 Pogo OA. Cloning of glycoprotein D cDNA, which encodes the major subunit of the Duffy blood group system and the receptor for the Plasmodium vivax malaria parasite. 446 Proc Natl Acad Sci USA. 1993;90:10793-10797. 447 Tournamille C, Colin Y, Cartron JP, Le Van Kim C. "Disruption of a GATA motif in the 7. 448 Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals." 449 Nat Genet. 1995;10(2):224–8. 450 Howes RE, Patil AP, Piel FB, Nyangiri OA, Kabaria CW, Gething PW, et al. The global 451 8.

distribution of the Duffy blood group. Nat Commun. 2011;2(4):266.

- 453 9. Musab MA, Albsheer KP, Safaa A, Mohammed E, Eiman G, Salma MA E al. Distribution
- of Duffy Phenotypes among Plasmodium vivax Infections in Sudan. Genes. 2019;10:417.
- 455 10. Popovici J, Roesch C, Rougeron V. The enigmatic mechanisms by which Plasmodium
- vivax infects Duffy-negative individuals. PLoS Pathog. 2020;16(2):e1008258.
- 457 11. Kepple D, Pestana K, Tomida J, Abebe A, Golassa L, Lo E. Alternative invasion
- 458 mechanisms and host immune response to Plasmodium vivax malaria: Trends and future
- directions. Microorganisms. 2021;9(1):1–17.
- 460 12. Daniels G. The molecular genetics of blood group polymorphism. Transplant
- 461 Immunology. 2005;14(3-4 SPEC. ISS.):143–53.
- 462 13. Gunalan K, Niangaly A, Thera MA, Doumbo OK, Miller LH. Plasmodium vivax
- Infections of Duffy-Negative Erythrocytes: Historically Undetected or a Recent
- Adaptation? Trends in Parasitology. 2018;34(5):420–9. Available from:
- 465 http://dx.doi.org/10.1016/j.pt.2018.02.006
- 466 14. Yazdanbakhsh K, Rios M, Storry JR, Kosower N, Parasol N, Chaudhuri A, et A.
- Molecular mechanisms that lead to reduced expression of duffy antigens. Transfusion.
- 468 2000;40(3):310–20.
- 469 15. Schmid P, Ravenell KR, Sheldon SL FW. DARC alleles and Duffy phenotypes in African
- 470 Americans. Transfusion. 2012;52:1260–7.
- 471 16. Loa E, Gianluca Russob, Pestanaa K, Kepplea D, Abageroc BR, Ghyslaine Bruna, et A.
- 472 Contrasting epidemiology and genetic variation of Plasmodium vivax infecting Duffy-
- 473 negative individuals across Africa. International Journal of Infectious Diseases.
- 474 2021;108:63–71.
- 475 17. Lo E, Yewhalaw D, Zhong D, Zemene E, Degefa T, Tushune K. Molecular epidemiology

- of Plasmodium vivax and Plasmodium falciparum malaria among Duffy-positive and 476 Duffy-negative populations in Ethiopia. Malaria Journal. 2015;14(84). 477 18. Carlos EC, Luiz CM, Álvaro AR, D'Almeida C, Vanja SC, Yuri G, et A. Duffy blood 478 group gene polymorphisms among malaria vivax patients in four areas of the Brazilian 479 Amazon region. Malaria Journal. 2007;6:167. 480 Roesch C, Id JP, Bin S, Run V, Kim S, Rakotomalala E, et al. Genetic diversity in two 481 19. Plasmodium vivax protein ligands for reticulocyte invasion. 2018;1–17. 482 20. Mendes C, Dias F, Figueiredo J, Mora VG, Cano J, de Sousa B, et A. Duffy Negative 483 Antigen Is No Longer a Barrier to Plasmodium vivax – Molecular Evidences from the 484 African West Coast (Angola and Equatorial Guinea). PLoS Negl Trop Dis. 485
- 486 2011;5(6):e1192.
- Wilairatana P, Masangkay FR, Kotepui KU, Milanez GDJ, Kotepui M. Prevalence and risk of Plasmodium vivax infection among Duffy negative individuals: a systematic review and meta analysis. Scientific Reports. 2022;1–13. Available from:
- 490 https://doi.org/10.1038/s41598-022-07711-5
- 491 22. Abate A, Bouyssou I, Mabilotte S, Lang CD, Dembele L, Menard D, et al. Vivax malaria
- in Duffy negative patients shows invariably low asexual parasitaemia : implication
- towards malaria control in Ethiopia. Malaria Journal. 2022;1–10. Available from:
- 494 https://doi.org/10.1186/s12936-022-04250-2
- 495 23. Tamirat Gebru Woldearegai, Peter G. Kremsner, Jürgen F. J. Kun BM. Plasmodium vivax
- 496 malaria in Duffy-negative individuals from Ethiopia. Transactions of The Royal Society
- of Tropical Medicine and Hygiene. 2013;107(5):328–31.
- 498 24. Debash H, Bisetegn H, Ebrahim H, Feleke DG, Gedefie A, Tilahun M, et al. Prevalence

and associated risk factors of malaria among febrile under-five children visiting health 499 facilities in Ziquala district, Northeast Ethiopia: A multicenter cross-sectional study. PLoS 500 ONE. 2022;17(10 October):1–13. Available from: 501 http://dx.doi.org/10.1371/journal.pone.0276899 502 25. Nicholas D, Julie S, Aung P, Hadjar S, Armedy H, Enny K, et A. Gametocyte Dynamics 503 504 and the Role of Drugs in Reducing the Transmission Potential of Plasmodium vivax. JID. 2013;208:802-12. 505 Canier L, Khim N, Kim S, Sluydts V, Heng S, Dourng D, et al. An innovative tool for 506 26. 507 moving malaria PCR detection of parasite reservoir into the field. Malaria Journal. 2013;12(1):1–12. 508 Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, et A. 27. 509 510 Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci USA. 2010;107(13):5967-71. 511 28. Miri-moghaddam E, Bameri Z, Mohamadi M. Duffy blood group genotypes among 512 malaria Plasmodium vivax patients of Baoulch population in southeastern Iran. Asian 513 Pacific Journal of Tropical Medicine. 2014;7(3):206–7. Available from: 514 http://dx.doi.org/10.1016/S1995-7645(14)60021-3 515 Ewa Ł, Nowak I, Czerwinski M, Wa K. Duffy blood group system – the frequency of Du 516 29. ff y antigen polymorphisms and novel mutations in the Polish population. 517 518 2019;(December 2018). 30. Guerra CA, Howes RE, Patil AP, Gething PW, van Boeckel TP, Temperley WH, et al. 519 The international limits and population at risk of Plasmodium vivax transmission in 2009. 520 521 PLoS Neglected Tropical Diseases. 2010;4(8).

522 31. Miller LH, Mason SJ, Clyde DF MM. The resistance factor to Plasmodium vivax in blacks: the Duffy-blood-group genotype, FyFy. N Engl J Med. 1976;295:302–4. 523 32. Rondônia D, Brasileira AO, Cavasini CE, José F, Pereira T, Ribeiro WL, et al. Duffy 524 blood group genotypes among malaria patients in Rondônia, Western Brazilian Amazon 525 Genótipos do sistema sanguíneo Duffy em pacientes maláricos. 2001;34(6):591–5. 526 527 33. Abdelraheem MH, Albsheer MMA, Mohamed HS, Amin M, Hamid MMA. Transmission of Plasmodium vivax in Duffy-negative individuals in central Sudan. Transactions of the 528 Royal Society of Tropical Medicine and Hygiene. 2016;110(4):258–60. 529 530 34. Zimmerman PA. Plasmodium vivax infection in Duffy-Negative People in Africa. Am J Trop Med Hyg. 2017;97. 531 35. Dongho GBD, Gunalan K, L'Episcopia M, Paganotti GM, Menegon M, Sangong RE, et 532 533 al. Plasmodium vivax Infections Detected in a Large Number of Febrile Duffy-Negative Africans in Dschang, Cameroon. American Journal of Tropical Medicine and Hygiene. 534 2021;104(3):987-92. 535 36. Oboh MA, Badiane AS, Ntadom G, Ndiaye YD, Diongue K, Diallo MA, et al. Molecular 536 identification of Plasmodium species responsible for malaria reveals Plasmodium vivax 537 538 isolates in Duffy negative individuals from southwestern Nigeria. Malaria Journal. 2018;17(1):1–12. Available from: https://doi.org/10.1186/s12936-018-2588-7 539 Ryan JR, Stoute JA, Amon J, Dunton RF, Mtalib R, Koros J, et al. Evidence for 540 37. 541 transmission of Plasmodium vivax among a Duffy antigen negative population in Western Kenya. American Journal of Tropical Medicine and Hygiene. 2006;75(4):575–81. 542 Brazeau NF, Whitesell AN, Doctor SM, Keeler C, Mwandagalirwa MK, Tshefu AK, et al. 543 38. 544 Plasmodium vivax infections in duffy-negative individuals in the democratic republic of

- the Congo. American Journal of Tropical Medicine and Hygiene. 2018;99(5):1128–33. 545 39. Poirier P, Doderer-Lang C, Atchade PS, Lemoine JP, De L'Isle MLC, Abou-Bacar A, et 546 al. The hide and seek of Plasmodium vivax in West Africa: Report from a large-scale 547 study in Beninese asymptomatic subjects. Malaria Journal. 2016;15(1):1–9. 548 Gruszczyk J, Kanjee U, Chan LJ, Menant S, Malleret B, Lim NTY, et al. Transferrin 40. 549 550 receptor 1 is a reticulocyte-specific receptor for Plasmodium vivax. Science. 2018;359(6371):48-55. 551 41. Wurtz N, Mint Lekweiry K, Bogreau H, Pradines B, Rogier C, Ould Mohamed Salem 552 553 Boukhary A, et al. Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Malaria Journal. 2011;10:1–8. 554 Kempi A, Knap O, Drozd A, Kaczmarczyk M, Parafiniuk M. Analysis for genotyping 42. 555 556 Duffy blood group in inhabitants of Sudan, the Fourth Cataract of the Nile. 2012;1–6. Gonzalez L, Veg J, Ramirez Jose L, Bedoya G C-F. Relationship between Duffy blood 557 43. groups genotypes and malaria infection in different ethnic groups of Choco-Colombia. 558 Colomb Med [online] 2012, vol43, n3, pp189-195. 2012;43(3):189–95. 559 Gaelle H, Mbenda N, Das A. Molecular Evidence of Plasmodium vivax Mono and Mixed 44. 560 561 Malaria Parasite Infections in Duffy-Negative Native Cameroonians. 2014;9(8):1–9. Oboh MA, Singh US, Ndiaye D, Badiane AS, Ali NA, Bharti PK, et al. Presence of 562 45. additional Plasmodium vivax malaria in Duffy negative individuals from Southwestern 563 564 Nigeria. Malaria Journal. 2020;1–8. Available from: https://doi.org/10.1186/s12936-020-03301-w 565
- Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, et al.
 Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy

people. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(13):5967-71. **Supporting information** Appendix A: Figures summarizing Sanger sequencing data Appendix B: Figures summarizing AMRS PCR-based allelic discrimination amplification curves in a control samples validated by PCR/Sanger sequencing